TMB as a biomarker of sensitivity to immunotherapy has fallen out of favor in the most recent updates of NCCN guidelines (NCCN, NSCLC v3.2022), with PD-L1 IHC expressing, patient status, extent of disease, and tumor histology guiding immunotherapy recommendations. This evidence concerns the gene CD274 and non-small cell lung carcinoma.